Jonathan Painter
Analyst · Joe Bess, ROTH Capital
Thanks, Tom. Hello, everyone. It’s my pleasure to brief you on our third quarter results from a weather weary East Coast. Overall, we had an outstanding quarter highlighted by record adjusted diluted earnings per share and particularly proud of our results as they were accomplished in an increasingly challenging macro environment. I’ll begin my remarks with an overview of our financial performance in Q3.
We finished the third quarter with revenues of $87 million, up 3% compared to the same period last year, despite a 4% unfavorable FX impact. Our gross margins were 43% in the quarter and demonstrate the sustainability of the productivity and efficiency gains that we’ve implemented. Most importantly, we generated adjusted diluted earnings per share of $0.66 in the third quarter, which was a 40% increase from Q3 of last year and the highest adjusted quarterly earnings per share in our history. Our EPS performance benefited from higher than expected revenues as well as a lower than expected tax rate, which Tom will discuss in his remarks. Our adjusted EBITDA for the third quarter was $12.1 million or 14% of revenue.
Finally, our cash flow for operations was quite good at $13 million and our cash less net debt at the end of the quarter was $42 million. In summary, I think it’s fair to say that our operations are executing extremely well. Beginning this quarter, we’ve combined our Doctoring, Water Management and Other product lines into a single product line for financial report and purposes, and we now refer to these products under the catchy name of Doctoring, Cleaning, and Filtration product line. I think it’s a sensible way to look at our revenue as these products typically operate as a single business.
Taking a look at our revenue performance by product line on slide six, our revenues in the third quarter were 3% higher compared to Q3 of last year, due largely to an increase in the aforementioned Doctoring, Cleaning and Filtration product line. Excluding FX, you can see that our Q3 revenues were up 7% compared to Q3 of last year. We had a disappointment in the quarter; it was our bookings of just over $69 million, which was down 27% from last year and is a reflection of the headwinds found in the macro economy.
A significant decline in capital bookings particularly in North America and Europe was the key driver leading to this decline. Our capital bookings were down more than 50% compared to a very strong Q3 of 2011, which included two large chemical pulping equipment orders with the value of nearly $20 million. On a sequential basis, our capital bookings were down 19%.
Looking a bit closer at our bookings by product line on slide seven, you can see that Stock Prep was down 48%. This was driven by a decrease in capital bookings due to the chemical pulping orders I just mentioned. In addition, our Fluid Handling line was down 19% due to slower activity in North America and Europe. On the other hand, our Doctoring, Cleaning and Filtration product line was up 3% as a result of stronger bookings in North America and China. The bookings and revenues trend chart on slide eight shows our quarterly revenue, which is the red line and our bookings, which are the blue bars. Revenues were up 4% sequentially led by our Stock Prep product line in China, which show revenues nearly doubled from the previous quarter.
While revenues saw a modest sequential increase in the third quarter, the market and economic factors I mentioned led to a 10% sequential decline in bookings in Q3. Lower bookings in North America and Europe were partially offset by increases in China, but the increases were not enough to prevent an overall drop in Q3 bookings.
Without a doubt our bookings, particularly for capital, had been adversely impacted by the concerns about the situation in Europe as well as the slowing global economy. That said, I do not think $69 million of bookings per quarter is the new normal. As I have noticed on previous calls, the timing of capital orders can also play a role in the quarterly booking rates and I believe that was the case in Q3, as we have several capital projects in the work - in the works, which I expect we’ll book in Q4.
As you can see from the chart on slide nine, while our Parts and Consumables business is considerably more resilient than our capital business, it is not immune to the headwinds we’re seeing in the market. Looking at bookings, which are shown in the blue bars, you can see the bookings in Q3 increased 6% compared to a fairly weak Q3 of last year, but were down 5% sequentially. The declines were in North America and Europe, where the third quarter tends to be one of our weaker quarters due to summer holidays and the timing of annual maintenance shutdowns. China continues to be a bright spot for our aftermarket business with bookings up 14% over Q3 of last year and 25% sequentially.
Similarly, our Parts and Consumables revenues were down 6% from Q3 of 2011, and 9% sequentially. Overall, our revenues for Parts and Consumables were $44 million, and represented approximately 50% of our Q3 revenues. I’d like to take the next few minutes to review our business activities in each of the major geographic regions of the world, starting with North America. Although, the economic recovery in North America has been sluggish, the paper industry has performed relatively well, and analysts expect producer margins to remain fairly stable in the near-term. In addition, input costs appear to be under control and inventory levels are fairly low.
Containerboard continues to be a bright spot with operating rates at 96% in September and slightly above 95% year-to-date. In addition, a $50 a ton price increase recently took effect. As you may recall, containerboard is an important grade for our business and containerboard and along with tissue typically makes up nearly 60% of our customer base.
Our Q3 revenues in North America were $35 million, up 9% compared to the same period last year. This uptick was due in large part to revenue increases in our Stock Prep product line. However, on a sequential basis, our North American revenues were down 13% due to weaker revenue performance in our Fluid Handling and our Stock Prep product line.
Bookings in North America were down 24% in Q3 compared to the same period last year and 10% sequentially. Our third quarter bookings reflected general slowdown in business activity in North America particularly for capital orders. The decrease in bookings was primarily driven by a decline in our Stock Prep and Fluid Handling capital business, which was down significantly compared to a very strong Q3 of last year.
Turning to Europe; Europe’s struggles with its sovereign debt issues continue to impact its economy and the regions slipped into recession going to 2013. As you might expect, this macro environment has impacted the demand for paper products. Our revenues in Europe were down 19% compared to Q3 of last year and down 4% sequentially. Bookings in Europe were down 48% compared to a strong Q3 of last year due largely to declines in our Stock Prep product line. As you can see from the chart, for the three quarters prior to Q3, the bookings rate was right around $19 million a quarter. Our quarterly bookings dropped to $15 million in Q3, but I believe that the timing of capital orders was a factor in this as I mentioned earlier.
Now let’s take a look at China. The economy in China continues to slow GDP growth dropping to 7.4% in Q3. Although, the rate of growth has slowed, the important thing is that it’s still growing and the economy continues to absorb the capacity that recently came online. We do see some producers beginning to make plans for capacity expansion, but the timing of orders remains uncertain. Our Q2 revenues in China increased 59% sequentially, but were down 8% year-over-year. The sequential increase was due in large part to higher revenues from our Stock Prep as well as our Fluid Handling product lines.
Bookings more than doubled from a weak Q3 of 2011 driven primarily by our Stock Prep product line. During the quarter, we booked several OCC Stock Prep systems with a combined value of $8 million and also booked an order for our tissue [indiscernible] with a value of approximately $1.2 million from a major tissue producer. Our efforts to increase our aftermarket business continued to produce results with bookings for aftermarket products up 14% over Q3 of last year and 25% sequentially.
Before finishing my regional review, I want to take a few - make a few comments on our business activity for the rest of the world. As you can see on slide 14, revenues have been on an upward trend for the past three years. Q3 revenues were up nearly 50% year-over-year and 27% sequentially, with the majority of these increases coming from South America and India. Bookings in the rest of the world regions generally have more variability due to the impact of capital orders. In Q3 for example, we booked an order for a Korean tissue producer for our next generation de-inking equipment as well as capital equipment orders for high-efficiency thermal compressors in Brazil and Ecuador.
A few weeks ago, our senior managers from around the world met to review our progress on key initiatives and outline our near-term and longer-term strategic goals. I can tell you that increasing our presence in the faster growing, developing world continues to be a major focus of ours, and we have several action plans in place to accomplish this that are being implemented. I believe as we expand our global footprint deeper into these developing regions, we will not only increase our revenues, but we will see a higher proportion of our revenues coming from these faster growing emerging markets.
I’d like to close my remarks with a few comments on our guidance for the fourth quarter and the full year 2012. Our biggest concerns going forward continue to be the weak global economic environment and uncertainty facing our customers. This uncertain macro environment has affected our bookings for the last several quarters, particularly for capital projects. For the fourth quarter, we expect to generate $0.35 to $0.37 of diluted earnings per share on revenues of $77 million to $79 million. We’re increasing our full year guidance and we now expect to achieve GAAP diluted earnings per share from continuing operations of $2.18 to $2.20 on revenues of $331 million to $333 million, and that’s up from our previous guidance of $2.05 to $2.10 on revenues of $305 million to $330 million.
I’ll now pass the call over to Tom for additional details on our financial performance. Tom?